NCT06948292CompletedPhase 2
Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics
Role of QRX-3 a Novel NAD Modulator in Ambulatory Chronic Kidney Patients
Source: ClinicalTrials.gov · Last updated 8 Sept 2025
Brief summary (registry, in English)
QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes intracellularly, repair of renal tubular injury and restoration of optimized renal function above baseline , will be studied in patients with progressive chronic kidney disease over 12 months . The result of the change in renal function expressed as creatinine GFR (Glomerular filtration decline) over the treatment duration will be compared in the treatment group will be compared to control group without the medication during that same period .
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 127 (actual)
- First submitted
- 21 Apr 2025
- Start date
- 1 Mar 2023
- Primary completion date
- 30 Aug 2024
- Lead sponsor
- Ebima Clifford Okundaye
- Diseases
- Chronic kidney disease
- NCT number
- NCT06948292
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 127
- From 1 Mar 2023 to the primary completion date, 30 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Symptomatic renal failure
- Presence of any suspected Acute renal failure superimposed
Other
- Rapid rate of decline in kidney function of \> 10 % over 3 months
- Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI
- No known reversible cause of renal decline
Who the study is looking for
- Patient with Chronic kidney disease stage 3-5
- Estimated Glomerular function by MDRD of less than 60mls/min
- Patients with declining renal function ( as measured by eGFR by MDRD )
- Rate of decline of eGFR over the last one year of less than 20%
- Negative Serology markers for CKD etiology
- Provider perceived adherence to study follow- up
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Neukidney Inc Coordinator of this site? Confirm its status | Pasedena | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.